Nabla Bio

Our goal is to make drug development a true design discipline — reducing trial-and-error so better medicines can reach patients faster and with greater confidence

Nabla Bio applies AI to drug design, aiming to make what is normally a slow, trial-and-error discovery process into a more predictable design discipline. The company combines de novo drug design with large-scale, human-relevant testing, building and owning its data, AI models, and integrated dry-lab and wet-lab systems as one connected engine rather than treating computation and lab testing as separate steps.

Its stated goal is to design medicines with the properties patients actually need, including binding, developability, cellular function, and in-vivo performance, so that new treatments can be safer, more precise, and able to reach targets that were previously out of reach. One output cited on the site is JAM-2, described as producing drug-like antibodies directly from the computer. This sits within the research category as an AI platform for biology and drug discovery rather than a general-purpose consumer tool.

Nabla Bio works by partnering directly with pharmaceutical companies rather than offering public pricing or self-serve access, so it operates on an enterprise, partnership basis. Pharmaceutical teams interested in AI-driven drug design can get in touch with Nabla Bio directly to discuss a partnership.

Category: Research. Pricing: enterprise. Visit website

Alternatives to Nabla Bio in Research

• Yila AI — Evidence-traceable research agent for literature review, PDF analysis, figures, and academic slides.
• Deep Search — AI web research, chat and public-information lookups
• ScholarIQ — ScholarIQ searches 470M+ articles from OpenAlex, ORCID and PubMed — and answers in plain language, with every claim cit…
• Tracetify — Evidence-led competitor launch intelligence for founders and marketers.
• XLeadForge — X outbound, queued daily in your voice
• Reverse Image Location — AI image geolocation and visual clue analysis